Clinical trial
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory…
NCT00279422 · Facet Biotech, Industry · Terminated
Key facts
| NCT number | NCT00279422 |
|---|---|
| Title | A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis |
| Official title | A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis |
| Lead sponsor | Facet Biotech, Industry |
| Collaborators | PDL BioPharma, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | visilizumab |
| Enrollment | 127 |
| Start date | Feb 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jan 19, 2006 |
| Last update posted | Mar 12, 2012 |
| Countries | Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Netherlands, Norway, Slovakia and 2 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: